Comparing of Melinta Therapeutics Inc. (MLNT) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)

Both Melinta Therapeutics Inc. (NASDAQ:MLNT) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Melinta Therapeutics Inc. 4 0.41 N/A -15.68 0.00
Spectrum Pharmaceuticals Inc. 9 9.59 N/A -1.37 0.00

Table 1 demonstrates Melinta Therapeutics Inc. and Spectrum Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 demonstrates the return on assets, net margins and return on equity of Melinta Therapeutics Inc. and Spectrum Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Melinta Therapeutics Inc. 0.00% -71.6% -32.3%
Spectrum Pharmaceuticals Inc. 0.00% -41.6% -30.4%

Volatility & Risk

Melinta Therapeutics Inc. is 321.00% more volatile than Standard and Poor’s 500 because the company has a beta of 4.21. In other hand, Spectrum Pharmaceuticals Inc. has beta of 2.54 which is 154.00% more volatile than Standard and Poor’s 500.

Analyst Ratings

The following table given below contains the ratings and recommendations for Melinta Therapeutics Inc. and Spectrum Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Melinta Therapeutics Inc. 0 0 0 0.00
Spectrum Pharmaceuticals Inc. 0 0 3 3.00

Melinta Therapeutics Inc.’s upside potential currently stands at 376.19% and an $14 consensus price target. Competitively Spectrum Pharmaceuticals Inc. has an average price target of $26.67, with potential upside of 201.02%. Based on the analysts view we can conclude, Melinta Therapeutics Inc. is looking more favorable than Spectrum Pharmaceuticals Inc.

Insider and Institutional Ownership

Institutional investors held 24.3% of Melinta Therapeutics Inc. shares and 75.6% of Spectrum Pharmaceuticals Inc. shares. Melinta Therapeutics Inc.’s share held by insiders are 0.3%. On the other hand, insiders held about 1.3% of Spectrum Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Melinta Therapeutics Inc. -1.73% -43.69% -5.92% -4.34% -84.58% 0.16%
Spectrum Pharmaceuticals Inc. -0.13% -11.45% -18.49% -32.32% -63.66% -13.37%

For the past year Melinta Therapeutics Inc. had bullish trend while Spectrum Pharmaceuticals Inc. had bearish trend.


On 7 of the 9 factors Spectrum Pharmaceuticals Inc. beats Melinta Therapeutics Inc.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.